Modality
Vaccine
MOA
IL-17i
Target
PRMT5
Pathway
JAK/STAT
Rett
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
~Sep 2017
→ ~Dec 2018
NDA/BLA
Mar 2019
→ Jan 2030
NDA/BLACurrent
NCT07306036
2,162 pts·Rett
2019-03→2029-04·Completed
NCT07966612
654 pts·Rett
2020-09→2030-01·Active
2,816 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-04-233.1y awayPh3 Readout· Rett
2030-01-183.8y awayPh3 Readout· Rett
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Complet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2029-04-23 · 3.1y away
Rett
Ph3 Readout
2030-01-18 · 3.8y away
Rett
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 |